PERRONE, GABRIELE
PERRONE, GABRIELE
Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino (NEUROFARBA)
A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy
2016 Mini, E; D’Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Tassi, R; Napoli, C; Picariello, L; Landini, I; Brugia, M; Mazzei, T; Tonelli, F; Nobili, S
Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents
2014 Messori L; Marchetti L; Massai L; Scaletti F; Guerri A; Landini I; Nobili S; Perrone G; Mini E; Leoni P; Pasquali M; Gabbiani C.
Druggable Targets in Pancreatic Adenocarcinoma
2014 Nobili S; Tassi R; Landini I; Perrone G; Napoli C; Mini E
Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies
2011 Crea F; Nobili S; Paolicchi E; Perrone G; Napoli C; Landini I; Danesi R; Mini E
Erratum: The inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on growth in human tumor cell lines with defective DNA damage response pathways (Oncology Research 25:9 (1441-1451) DOI: 10.3727/096504017X14926854178616)
2018 Mini, Enrico; Landini, Ida; Lucarini, Laura; Lapucci, Andrea; Napoli, Cristina; Perrone, Gabriele; Tassi, Renato; Masini, Emanuela; Moroni, Flavio; Nobili, Stefania
Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma
2023 Perrone, Gabriele; Rigacci, Luigi; Urru, Sara; Kovalchuk, Sofya; Brugia, Marco; Fabbri, Alberto; Iovino, Lorenzo; Puccini, Benedetta; Cencini, Emanuele; Orciuolo, Enrico; Birtolo, Silvia; Melosi, Alessandro; Santini, Simone; Landini, Ida; Roviello, Giandomenico; Santi, Raffaella; Macciotta, Alessandra; Ricceri, Fulvio; Bosi, Alberto; Bocchia, Monica; Petrini, Mario; Mini, Enrico; Nobili, Stefania
Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors.
2015 Tassi, R; Perrone, G; Brugia, M; Simi, L; Petreni, P; Mori, E; Landini, I; Pazzagli, M; Mazzei, T; Mini, E; Nobili, S
Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy
2016 Tassi, R; Mini, E; D'Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Napoli, C; Picariello, L; Brugia, M; Landini, I; Mazzei, T; Tonelli, F; Nobili, S
Identification Of Pharmacogenomic Markers Of Clinical Efficacy In A Dose-Dense Therapy Regimen (R-Chop14) In Diffuse Large B Cell Lymphoma
2014 Nobili S; Napoli C; Puccini B; Landini I; Perrone G; Brugia M; Benelli G; Doria M; Martelli M; Finolezzi E; Di Rocco A; Del Fava E; Rigacci L; Di Lollo S; Bosi A; Mini E.
Identificazione di MTHFR 1298A>C come marcatore predittivo di sopravvivenza in due coorti di pazienti con carcinoma colorettale (stadio II e III) trattati con chemioterapia adiuvante a base di fluoropirimidine con o senza oxaliplatino
2014 Perrone G.
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin
2015 Cecchin E; Perrone G; Nobili S; Polesel J; De Mattia E; Zanusso C; Petreni P; Lonardi S; Pella N; D'Andrea M; Errante D; Rizzolio F; Mazzei T; Landini I; Mini E; Toffoli G.
Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge
2022 Lavacchi D.; Landini I.; Perrone G.; Roviello G.; Mini E.; Nobili S.
Pharmacogenomic Markers of Clinical Efficacy in a Dose-Dense Therapy Regimen (R-CHOP14) in Diffuse Large B Cell Lymphoma
2011 Napoli C; Nobili S; Landini I; Perrone G; Valenti A; Brugia M; Puccini B; Antognoli G; Doria M; Martelli M; Finolezzi E; Rigacci L; Di Lollo S; Bosi A; Mini E
Pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B cell lymphoma: preliminary results
2010 Napoli C; Nobili S; Landini I; Perrone G; Puccini B; Antognoli G; Doria M; Martelli M; Finolezzi E; Rigacci L; Di Lollo S; Bosi A; Mini E
Pharmacological modulation of protein kinase C for overcoming drug resistance in colorectal cancer. Preliminary results of in vitro studies.
2016 Mini, E; Landini, I; Napoli, C; Nobili, S; Perrone, G; Lapucci, A
PNN and KCNQ1OT1 can predict the efficacy of adjuvant fluoropyrimidine-based chemotherapy in colorectal cancer patients
2021 Lapucci, Andrea; Perrone, Gabriele; Di Paolo, Antonello; Napoli, Cristina; Landini, Ida; Roviello, Giandomenico; Calosi, Laura; Naccarato, Antonio Giuseppe; Falcone, Alfredo; Bani, Daniele; Mini, Enrico; Nobili, Stefania
Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipy(c.)
2014 Gamberi T; Massai L; Magherini F; Landini I; Fiaschi T; Scaletti F; Gabbiani C; Bianchi L; Bini L; Nobili S; Perrone G; Mini E; Messori L; Modesti A
RNA sequencing reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy
2016 Mini, E.; D’ Aurizio, R.; Perrone, G.; Magi, A.; Lapucci, A.; Tassi, R.; Napoli, C.; Picariello, L.; Landini, I.; Nobili, S.
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy
2019 Mini E.; Lapucci A.; Perrone G.; D'Aurizio R.; Napoli C.; Brugia M.; Landini I.; Tassi R.; Picariello L.; Simi L.; Mancini I.; Messerini L.; Magi A.; Pinzani P.; Mazzei T.; Tonelli F.; Nobili S.
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study.
2017 Rigacci, L; Perrone, G; Nobili, S; Kovalchuk, S; Puccini, B; Tassi, R; Brugia, M; Landini, I; Mannelli, L; Benelli, G; Napoli, C; Cencini, E; Fabbri, A; Iovino, L; Petrini, M; Birtolo, S; Melosi, A; Santini, S; Bernardeschi, P; Bosi, A; Mini, E
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy | 2016 | Mini, E; D’Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Tassi, R; Napoli, C; Picariello, L; Landini, I; Brugia, M; Mazzei, T; Tonelli, F; Nobili, S | |
| Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents | 2014 | Messori L; Marchetti L; Massai L; Scaletti F; Guerri A; Landini I; Nobili S; Perrone G; Mini E; Leoni P; Pasquali M; Gabbiani C. | |
| Druggable Targets in Pancreatic Adenocarcinoma | 2014 | Nobili S; Tassi R; Landini I; Perrone G; Napoli C; Mini E | |
| Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies | 2011 | Crea F; Nobili S; Paolicchi E; Perrone G; Napoli C; Landini I; Danesi R; Mini E | |
| Erratum: The inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on growth in human tumor cell lines with defective DNA damage response pathways (Oncology Research 25:9 (1441-1451) DOI: 10.3727/096504017X14926854178616) | 2018 | Mini, Enrico; Landini, Ida; Lucarini, Laura; Lapucci, Andrea; Napoli, Cristina; Perrone, Gabriele; Tassi, Renato; Masini, Emanuela; Moroni, Flavio; Nobili, Stefania | |
| Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma | 2023 | Perrone, Gabriele; Rigacci, Luigi; Urru, Sara; Kovalchuk, Sofya; Brugia, Marco; Fabbri, Alberto; Iovino, Lorenzo; Puccini, Benedetta; Cencini, Emanuele; Orciuolo, Enrico; Birtolo, Silvia; Melosi, Alessandro; Santini, Simone; Landini, Ida; Roviello, Giandomenico; Santi, Raffaella; Macciotta, Alessandra; Ricceri, Fulvio; Bosi, Alberto; Bocchia, Monica; Petrini, Mario; Mini, Enrico; Nobili, Stefania | |
| Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors. | 2015 | Tassi, R; Perrone, G; Brugia, M; Simi, L; Petreni, P; Mori, E; Landini, I; Pazzagli, M; Mazzei, T; Mini, E; Nobili, S | |
| Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy | 2016 | Tassi, R; Mini, E; D'Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Napoli, C; Picariello, L; Brugia, M; Landini, I; Mazzei, T; Tonelli, F; Nobili, S | |
| Identification Of Pharmacogenomic Markers Of Clinical Efficacy In A Dose-Dense Therapy Regimen (R-Chop14) In Diffuse Large B Cell Lymphoma | 2014 | Nobili S; Napoli C; Puccini B; Landini I; Perrone G; Brugia M; Benelli G; Doria M; Martelli M; Finolezzi E; Di Rocco A; Del Fava E; Rigacci L; Di Lollo S; Bosi A; Mini E. | |
| Identificazione di MTHFR 1298A>C come marcatore predittivo di sopravvivenza in due coorti di pazienti con carcinoma colorettale (stadio II e III) trattati con chemioterapia adiuvante a base di fluoropirimidine con o senza oxaliplatino | 2014 | Perrone G. | |
| MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin | 2015 | Cecchin E; Perrone G; Nobili S; Polesel J; De Mattia E; Zanusso C; Petreni P; Lonardi S; Pella N; D'Andrea M; Errante D; Rizzolio F; Mazzei T; Landini I; Mini E; Toffoli G. | |
| Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge | 2022 | Lavacchi D.; Landini I.; Perrone G.; Roviello G.; Mini E.; Nobili S. | |
| Pharmacogenomic Markers of Clinical Efficacy in a Dose-Dense Therapy Regimen (R-CHOP14) in Diffuse Large B Cell Lymphoma | 2011 | Napoli C; Nobili S; Landini I; Perrone G; Valenti A; Brugia M; Puccini B; Antognoli G; Doria M; Martelli M; Finolezzi E; Rigacci L; Di Lollo S; Bosi A; Mini E | |
| Pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B cell lymphoma: preliminary results | 2010 | Napoli C; Nobili S; Landini I; Perrone G; Puccini B; Antognoli G; Doria M; Martelli M; Finolezzi E; Rigacci L; Di Lollo S; Bosi A; Mini E | |
| Pharmacological modulation of protein kinase C for overcoming drug resistance in colorectal cancer. Preliminary results of in vitro studies. | 2016 | Mini, E; Landini, I; Napoli, C; Nobili, S; Perrone, G; Lapucci, A | |
| PNN and KCNQ1OT1 can predict the efficacy of adjuvant fluoropyrimidine-based chemotherapy in colorectal cancer patients | 2021 | Lapucci, Andrea; Perrone, Gabriele; Di Paolo, Antonello; Napoli, Cristina; Landini, Ida; Roviello, Giandomenico; Calosi, Laura; Naccarato, Antonio Giuseppe; Falcone, Alfredo; Bani, Daniele; Mini, Enrico; Nobili, Stefania | |
| Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipy(c.) | 2014 | Gamberi T; Massai L; Magherini F; Landini I; Fiaschi T; Scaletti F; Gabbiani C; Bianchi L; Bini L; Nobili S; Perrone G; Mini E; Messori L; Modesti A | |
| RNA sequencing reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy | 2016 | Mini, E.; D’ Aurizio, R.; Perrone, G.; Magi, A.; Lapucci, A.; Tassi, R.; Napoli, C.; Picariello, L.; Landini, I.; Nobili, S. | |
| RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy | 2019 | Mini E.; Lapucci A.; Perrone G.; D'Aurizio R.; Napoli C.; Brugia M.; Landini I.; Tassi R.; Picariello L.; Simi L.; Mancini I.; Messerini L.; Magi A.; Pinzani P.; Mazzei T.; Tonelli F.; Nobili S. | |
| Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. | 2017 | Rigacci, L; Perrone, G; Nobili, S; Kovalchuk, S; Puccini, B; Tassi, R; Brugia, M; Landini, I; Mannelli, L; Benelli, G; Napoli, C; Cencini, E; Fabbri, A; Iovino, L; Petrini, M; Birtolo, S; Melosi, A; Santini, S; Bernardeschi, P; Bosi, A; Mini, E |